Weekly Analysts’ Ratings Changes for X4 Pharmaceuticals (XFOR)

Several analysts have recently updated their ratings and price targets for X4 Pharmaceuticals (NASDAQ: XFOR):

• 12/8/2025 – X4 Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/5/2025 – X4 Pharmaceuticals was given a new $10.00 price target on by analysts at Stifel Nicolaus. They now have a “buy” rating on the stock.
• 12/1/2025 – X4 Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/30/2025 – X4 Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/26/2025 – X4 Pharmaceuticals was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 11/24/2025 – X4 Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/22/2025 – X4 Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/18/2025 – X4 Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/5/2025 – X4 Pharmaceuticals was given a new $7.50 price target on by analysts at Stifel Nicolaus.
• 10/21/2025 – X4 Pharmaceuticals was upgraded by analysts at Zacks Research to a “strong-buy” rating.

Insider Buying and Selling at X4 Pharmaceuticals

In related news, Chairman Adam R. Craig bought 86,206 shares of the company’s stock in a transaction on Thursday, October 23rd. The shares were purchased at an average price of $2.90 per share, for a total transaction of $249,997.40. Following the completion of the transaction, the chairman directly owned 376,087 shares in the company, valued at approximately $1,090,652.30. The trade was a 29.74% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 2.15% of the stock is owned by insiders.

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.